...-effective versus bevacizu­mab plus capecitabine according to probabilistic sensitivity analysis. Conclusions: Based on the results of the analysis, bevacizumab plus paclitaxel is unlikely to be a cost-effective option for patients with HER2-negative locally recurrent or metastatic breast cancer compared...

..., instructions or products referred to in the content or advertisements. 2017 Rationing cancer care Cost-effectiveness Withholding beneficial treatment Role of oncologists Quantitative and qualitative data As a consequence of new diagnostic and therapeutic options in cancer treatment...